Aytu BioPharma (NASDAQ:AYTU) Posts Earnings Results, Beats Expectations By $0.24 EPS

Aytu BioPharma (NASDAQ:AYTU) issued its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.24, Zacks reports. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The company had revenue of $16.11 million during the quarter, compared to analyst estimates of $12.28 million.

Here are the key takeaways from Aytu BioPharma’s conference call:

• EXXUA revenue rose to $3.9 million in fiscal Q4 from $2.4 million in Q3, while prescriptions increased to 3,323 for the quarter and reached a weekly record of nearly 400 in early September. Management highlighted broad prescribing across territories, growing refills, favorable payer approval rates, and encouraging physician feedback.
• EXXUA’s commercial rollout has involved significant sales-force turnover and a lengthy ramp period. The field team fell from 43 representatives in March to 32 in July before recovering to approximately 42, and management said new representatives may require six to nine months to become fully productive.
• Aytu returned to positive adjusted EBITDA of $0.5 million in Q4, generated $3.3 million of operating cash flow for fiscal 2026, repaid its revolver after year-end, and reduced interest expense through debt paydown. Cash was relatively stable at $26.3 million at fiscal year-end despite continued deleveraging.
• Fiscal 2027 will include increased EXXUA investment, with cash-based operating expenses expected at $45 million to $49 million and up to $6 million allocated to sales, marketing, and education. Management expects weaker adjusted EBITDA and cash flow in the first half because of launch spending and ADHD seasonality, but forecasts positive adjusted EBITDA over the six months ending June 2027 and consolidated gross margins approaching 66%–67% in Q4.
• The ADHD portfolio generated $10.4 million of Q4 revenue, up sequentially, while Adzenys and its authorized generic retained about 80% of prescriptions in their market. Cotempla’s authorized generic is gaining prescriptions, and Teva has not yet launched its competing generic, creating potential upside to management’s assumptions.

Aytu BioPharma Price Performance

NASDAQ:AYTU opened at $2.23 on Wednesday. Aytu BioPharma has a one year low of $1.65 and a one year high of $3.07. The stock has a market cap of $23.93 million, a PE ratio of -0.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The stock has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.33.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Citigroup restated a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Finally, Ascendiant Capital Markets boosted their price target on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.75.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.